EPOS-IASIS - An Innovative Company - An EIC Declared Global Innovator

EPOS-IASIS is dedicated to addressing the evolving challenges and gaps in chronic disease management. Our vision is to empower individuals at risk of developing systemic malignancies and other multifactorial diseases by providing personalized and multimodality platforms. These innovative solutions, designed for in vivo, minimally invasive, long-term, and sensitive detection, monitoring, and intervention, aim to revolutionize patient care. By significantly enhancing prognosis and survival rates, our platforms will contribute to a paradigm shift in healthcare. EPOS-IASIS envisions leading the way into the multi-billion-dollar field of multifactorial disease molecular theranostics, where precision and efficacy converge for a healthier future. EPOS-IASIS has amassed expertise in translational nanotheranostics, molecular imaging and cell-based technologies, with an emphasis on hybrid (cell + electronics) systems, harnessing molecules and light for faster diagnosis and better prognosis. EPOS-IASIS has established the sole multimodal In Vivo imaging platform on the island (mCT-3DOI-FMT) and the first setting for BRET/FRET technology in the region. It is considered a regional leader in translational nanotheranostics. In the first 13 years of life, EPOS-IASIS has coordinated or participated as a major partner in numerous national and one major FP7-IAPP and H2020 grants, bridging the academic with the entrepreneurial spirit across sectors, amassing more than 5M Euros, including MDCAs, HORIZON-WIDESPREAD-Teaming I (Precision Technologies) and FETOpen. EPOS-IASIS has secured one EPO, one PCT and two USPO patents in theranostics, new CNT-delivery systems for brain tumors and on multifunctional conjugates for metastatic Cancer.